COSTS OF INTRODUCING AUTOLOGOUS BMT IN THE TREATMENT OF LYMPHOMA AND ACUTE-LEUKEMIA IN THE NETHERLANDS

Autor: GROOT, CAUD, OKHUIJSEN, SY, HAGENBEEK, A, HUIJGENS, PC, VANIMHOFF, GW, LOWENBERG, B, VERDONCK, LF, RUTTEN, FFH

Publikováno v: Bone marrow transplantation, 15(4), 605-610. Nature Publishing Group

In a retrospective study we calculated the costs of introducing autologous BMT in the treatment of patients with malignant lymphoma and acute leukaemia in The Netherlands. The cost analysis has been performed in five university hospitals and one canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::610abf70a39fdbe51d5f340fbce64acb
https://research.rug.nl/en/publications/813f7113-f68b-48ea-9a63-872e73d6e33d

Quality of integrated care for patients with nonsmall cell lung cancer: variations and determinants of care.

Autor: Ouwens MM; Centre for Quality of Care Research (WOK), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. M.Ouwens@kwazo.umcn.nl, Hermens RR, Termeer RA, Vonk-Okhuijsen SY, Tjan-Heijnen VC, Verhagen AF, Hulscher MM, Marres HA, Wollersheim HC, Grol RP

Publikováno v: Cancer [Cancer] 2007 Oct 15; Vol. 110 (8), pp. 1782-90.

[An estimate of the intramural costs of the placement of a total hip prosthesis].

Autor: Okhuijsen SY; Academisch Ziekenhuis, afd. Orthopedie, GA Utrecht., Dhert WJ, Faro LM, Keet JG, Schrijvers AJ, Verbout AJ

Publikováno v: Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 1998 Jun 20; Vol. 142 (25), pp. 1450-5.

Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.

Autor: Uyl-de Groot CA; Institute for Medical Technology Assessment/Department of Health Care Management and Policy, Erasmus University Rotterdam, The Netherlands., Okhuijsen SY, Hagenbeek A, Huijgens PC, van Imhoff GW, Löwenberg B, Verdonck LF, Rutten FF

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 1995 Apr; Vol. 15 (4), pp. 605-10.

Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group.

Autor: Guirado M; Medical Oncology Department, Hospital General Universitario de Elche, 03203, Elche, Spain., Sanchez-Hernandez A; Medical Oncology Department, Consorcio Hospitalario Provincial de Castellón, 12002, Castellón de la Plana, Spain., Pijuan L; Pathology Department, Bellvitge University Hospital, 08907, L'Hospitalet de Llobregat, Spain., Teixido C; Thoracic Oncology Unit, Department of Pathology, IDIBAPS, Hospital Clinic of Barcelona, C. de Villarroel, 170, 08036, Barcelona, Spain. teixido@clinic.cat., Gómez-Caamaño A; Department of Radiation Oncology, Hospital Clínico Universitario Santiago de Compostela, 15706, Santiago de Compostela, Spain., Cilleruelo-Ramos Á; Thoracic Surgery Department, Hospital Clínico Universitario Valladolid, 47005, Valladolid, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Mar; Vol. 24 (3), pp. 446-459. Date of Electronic Publication: 2021 Oct 19.